CG Oncology Pivot-006 Data in Early June Seen as 'Complex' Catalyst, RBC Says

MT Newswires Live00:30

CG Oncology's (CGON) Pivot-006 study, currently evaluating Cretostimogene Grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer, is a "complex" catalyst, RBC Capital Markets said in a Monday note.

The firm said complexity stems from limited historical data to anchor readout expectations, combined with a recent run-up in shares and a more challenging tactical setup ahead of the catalyst.

RBC expects data from the trial in early June and models Cretostimogene delivering a nearly 40% risk reduction, which it estimates would drive about 20% upside in the stock. The firm also highlights a greater than $1.2 billion US opportunity in intermediate-risk disease, adding to the drug's established profile in high-risk non-muscle invasive bladder cancer.

Other key catalysts include additional clinical readouts across its bladder cancer program and a potential BLA filing in H2, RBC said.

The firm has an outperform, speculative risk rating on the stock and raised its price target to $79 from $73.

Price: 68.66, Change: -0.02, Percent Change: -0.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment